GLPwatch
In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status.
Ann Intern Med · 2024
Last updated 2026-05-28In a study of 529 adults with heart failure with preserved ejection fraction (HFpEF) and obesity, those who took semaglutide for 52 weeks lost an average of 10.7% of their body weight compared to 1.8% in the placebo group. Semaglutide also led to greater improvements in health status, including symptoms and physical limitations, compared to placebo.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2024 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.51 |
| NIH percentile | 30 |
| Molecules | semaglutide |
| Conditions studied | Obesity, Heart Failure |
Abstract
Kosiborod MN, Verma S, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Circulation. 2024;149:204-216. 37952180.
Verbatim abstract via PubMed 38710083 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.